Gabapentin Tablet
Product Images NDC 50090-6189

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-6189). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sideeffects (Sideeffects)

A text excerpt listing side effects or warnings associated with a medication, including symptoms such as lack of coordination, viral infection, difficulty with speaking, tremor, swelling of legs and feet, tiredness, fever, drowsiness, nausea and vomiting, jerky movements, double vision, and unusual eye movement.*

FDA Label Image

Table-1 (Table1)

A data table titled 'Gabapentin Dosage Based on Renal Function' detailing dosage adjustments according to renal function measured by creatinine clearance. The table shows columns for renal function ranges, total daily dose ranges in mg/day, and dose regimens in mg with frequency (TID, BID, QD). A second section outlines post-hemodialysis supplemental doses in mg. Footnotes define abbreviations and provide dosing guidance for patients with varying creatinine clearance and hemodialysis.*

FDA Label Image

Table-2 (Table2)

A data table titled 'TABLE 2 Risk by Indication for Antiepileptic Drugs in the Pooled Analysis' showing risk metrics for epilepsy, psychiatric, and other indications. Columns include placebo patients with events per 1,000 patients, drug patients with events per 1,000, relative risk comparing drug to placebo patients, and risk difference representing additional drug patients with events per 1,000.*

FDA Label Image

Table-3 (Table3)

A table titled 'Adverse Reactions in Pooled Placebo-Controlled Trials in Postherpetic Neuralgia' comparing the percentage of adverse reactions reported for Gabapentin (N=336) versus placebo (N=227). It lists various body systems and specific reactions such as asthenia, infection, diarrhea, peripheral edema, dizziness, and somnolence with corresponding percentages for each group.*

FDA Label Image

Table-4 (Table4)

A data table titled 'Adverse Reactions in Pooled Placebo-Controlled Add-On Trials in Epilepsy Patients
3 years of age' comparing percentages of various adverse reactions between gabapentin and placebo groups. Categories include body as a whole, cardiovascular, digestive, nervous, respiratory, skin, urogenital systems, and special senses, with specific reactions and corresponding percentages for gabapentin (N=543) and placebo (N=378).*

FDA Label Image

Table-5 (Table5)

Table 5 showing adverse reactions in pediatric epilepsy patients ages 3 to 12 years from a placebo-controlled add-on trial comparing gabapentin and placebo. The table presents percentages of patients experiencing side effects across body systems, including viral infection, fever, increased weight, fatigue, digestive, nervous, and respiratory system symptoms, with data for gabapentin (N=119) and placebo (N=128).*

FDA Label Image

Table-6 (Table6)

A data table titled 'Controlled PHN Studies: Duration, Dosages, and Number of Patients' showing two studies with durations of 8 weeks and 7 weeks. It lists gabapentin target doses in mg/day for each study, the number of patients receiving gabapentin, and the number of patients receiving placebo. A footnote states doses were given in 3 divided doses (TID).*

FDA Label Image

Clcr (Clcr)

An illustration showing the formula to calculate creatinine clearance (CLCr), which factors age, weight, and serum creatinine levels, with an adjustment multiplier for female patients.*

FDA Label Image

Figure-1 (Figure1)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' compares mean pain scores over an 8-week period between placebo and Gabapentin 3600 mg/day. The y-axis represents mean pain scores from 0 to 10, and the x-axis represents weeks, including a baseline. The graph shows a decline in mean pain scores for Gabapentin during a 4-week dose titration followed by a 4-week fixed dose period, while placebo scores remain relatively stable.*

FDA Label Image

Figure-2 (Figure2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. The x-axis represents weeks from baseline to 7, and the y-axis shows mean pain scores from 0 to 10. Three lines depict different groups: placebo (circle markers), gabapentin 1800 mg/day (triangle markers), and gabapentin 2400 mg/day (open triangle markers). The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure-3 (Figure3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. It compares the percentage of responders between placebo (PBO) and gabapentin (GBP) at doses of 1800 mg, 2400 mg, and 3600 mg, demonstrating higher response rates in gabapentin groups. Significance levels are indicated with asterisks.*

FDA Label Image

Figure-4 (Figure4)

A chart showing the responder rate in patients receiving Gabapentin as an adjunctive therapy for partial seizures, expressed as difference from placebo by daily dose in mg across three studies (Study a, b, and c). The y-axis depicts percentage difference, and the x-axis shows daily doses of 600, 900, 1200, and 1800 mg. Data points vary by study and dose.*

FDA Label Image

Label Image (Lbl500906189)

Label for GABAPENTIN 800 mg oral tablets by A-S Medication Solutions. The label states each tablet contains 800 mg of gabapentin, with storage instructions to keep at 77 degrees Fahrenheit. The package contains 60 tablets. It includes the product NDC (50090-6189-0) and the labeler location, Libertyville, IL 60048.*

FDA Label Image

Struc (Struct)

Chemical structure of gabapentin, showing a cyclohexane ring with two substituents: a methylamine group (CH2NH2) and an acetic acid group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.